Krishna Namburi, MD
Cardiovascular Disease · Terre Haute, INNPI 1942319934
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,410 of the $73,481 with a category attached, or 76.8%. Johnson & Johnson accounts for 83.0% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $16,550 and has fallen 83.4% since, to $2,744 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 727 payments — averaging $101.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$61K
- Boston Scientific$3K
- Abbott$2K
- Novartis$1K
- AstraZeneca$819
- E.r. Squibb & Sons, L.L.C.$726
- plus $5K from 34 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$56,41077%
- Travel & lodging$1,5462%
- Food & beverage$14,95920%
- Education$2660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 198 | $60,996 |
| Boston Scientific | 114 | $2,505 |
| Abbott | 33 | $1,818 |
| Novartis | 65 | $1,123 |
| AstraZeneca | 29 | $819 |
| E.r. Squibb & Sons, L.L.C. | 43 | $726 |
| Medtronic(2 entities) | 16 | $616 |
| Merck | 29 | $545 |
| Amgen | 25 | $497 |
| Pfizer | 30 | $404 |
| Boehringer Ingelheim | 20 | $365 |
| Sanofi-aventis U.S. LLC | 17 | $313 |
| Amarin Pharma, Inc. | 28 | $306 |
| Novo Nordisk | 15 | $284 |
| Edwards Lifesciences | 2 | $236 |
| Bayer | 5 | $198 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $186 |
| Shockwave Medical, Inc | 3 | $185 |
| Actelion Pharmaceuticals US, Inc. | 6 | $184 |
| Philips North America LLC | 3 | $164 |
| Cardiovascular Systems Inc. | 1 | $146 |
| Endologix LLC | 1 | $145 |
| Chiesi USA, Inc. | 6 | $109 |
| Astellas Pharma US Inc | 1 | $90 |
| Baxter Healthcare | 1 | $78 |
| Cardinal Health 200 LLC | 1 | $61 |
| Biotronik Inc. | 2 | $49 |
| Penumbra, Inc. | 2 | $43 |
| United Therapeutics Corporation | 2 | $36 |
| Cordis US CORP. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Acist Medical Systems, Inc. | 1 | $28 |
| Gilead | 2 | $26 |
| Teleflex LLC | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Abiomed | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$58,649
- CARDIOMEMS$775
- MitraClip$291
- VERQUVO$241
- SYMPLICITY G3$157
- GENERAL - THERAPIES$155
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$150
- Diamondback Coronary$146
- AVVIGO Guidance System$146
- Ovation iX Iliac Stent Graft$145
- ONYX FRONTIER$144
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$130
- FARXIGA$125
- Adempas$123
- (9520) IGT Devices Undivided$123
- CAMZYOS$121
- Edwards SAPIEN 3 Transcatheter Heart Valve$106
How this compares
$73,481 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 826 | $809,524 |
| EliquisApixaban | 478 | $465,630 |
| EntrestoSacubitril/Valsartan | 288 | $281,838 |
| JardianceEmpagliflozin | 136 | $109,292 |
| Repatha SureclickEvolocumab | 130 | $104,934 |
| BrilintaTicagrelor | 125 | $86,741 |
| MultaqDronedarone Hcl | 18 | $26,974 |
| FarxigaDapagliflozin Propanediol | 22 | $23,398 |
| Metoprolol Succinate | 982 | $11,323 |
| Repatha SyringeEvolocumab | 14 | $11,142 |
| Propafenone Hcl | 276 | $9,332 |
| Amiodarone Hcl | 465 | $9,292 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 296 | $8,342 |
| Ranolazine ErRanolazine | 70 | $8,341 |
| ClopidogrelClopidogrel Bisulfate | 768 | $8,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $60,996 | $809,524826 claims |
| PfizerEliquis | $404 | $465,630478 claims |
| NovartisEntresto | $1,123 | $281,838288 claims |
| AstraZenecaBrilinta, Farxiga | $819 | $110,139147 claims |
| Boehringer IngelheimJardiance | $365 | $109,292136 claims |
| Sanofi-aventis U.S. LLCMultaq | $313 | $26,97418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Terre Haute
- Tony NasserTerre Haute$52K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.